Christoffer Læssøe Madsen

Christoffer Læssøe Madsen

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2014 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
HFHans C. Fledelius
Hans C. Fledelius
LSLisbeth Sandfeld
Lisbeth Sandfeld
ÅRÅse Krogh Rasmussen
Åse Krogh Rasmussen
CMChristoffer Læssøe Madsen
Christoffer Læssøe Madsen
UFUlla Feldt‐Rasmussen
Ulla Feldt‐Rasmussen

10 December 2018 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
CMChristoffer Læssøe Madsen
Christoffer Læssøe Madsen
HGHenrik Granqvist
Henrik Granqvist
JPJørgen H Petersen
Jørgen H Petersen
ÅRÅse K Rasmussen
Åse K Rasmussen
ALAllan M Lund
Allan M Lund
UFUlla Feldt-Rasmussen
Ulla Feldt-Rasmussen
Nephropathy is common in Fabry disease (FD). Prior studies of renal function during enzyme replacement therapy (ERT) have primarily used estimated glomerular filtration rate (eGFR). We studied the attrition of renal function in FD by measured GFR (mGFR) and urine protein excretion, and explored the influence of age. This was a long-term observational study of a nationwide, family-screened cohort of FD patients. All Danish genetically verified FD patients on ERT, without end-stage renal disease at baseline and with three or more mGFR values were included. In all, 52 patients with consecutive mGFR values (n = 841) over median 7 years (range 1–13) were evaluated. Blood pressure remained normal and urine protein excretion was unchanged. Plasma globotriaosylceramide (Gb-3) levels normalized while plasma lyso-Gb-3 remained abnormal in 34% of patients. Baseline mGFR was 90 ± 3 mL/min/1.73 m2 and rate of renal function loss 0.9 ± 0.2 mL/min/1.73 m2/year. Baseline eGFR was 97 ± 5 mL/min/1.73 m2 and rate of renal function loss 0.8 ± 0.3 mL/min/1.73 m2/year. mGFR was age- adjusted to renal healthy non-FD subjects, giving a standard deviation score of −0.8 ± 0.2 with an annual slope of −0.03 ± 0.01 (P = 0.099), without differences between genders. Age grouping of age-adjusted data showed exaggerated renal function loss with age. Urine albumin–creatinine ratio (UACR) >300 mg/g was associated with faster renal function loss, independent of baseline mGFR, age and gender. ERT-treated FD patients did not have a faster attrition of renal function than renal healthy non-FD subjects (background population). The rate of renal function loss with age was independent of gender and predicted by high UACR. We suggest cautious interpretation of non-age-adjusted FD renal data.

14 April 2018
Verified
Book Chapter
Closed access
PDF file
JLJosefine Loeb
Josefine Loeb
UFUlla Feldt-Rasmussen
Ulla Feldt-Rasmussen
CMChristoffer Læssøe Madsen
Christoffer Læssøe Madsen
AVAsmus Vogel
Asmus Vogel

8 September 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BLBjørn Strøier Larsen
Bjørn Strøier Larsen
FOFlemming Javier Olsen
Flemming Javier Olsen
DADitte Madsen Andersen
Ditte Madsen Andersen
CMChristoffer Læssøe Madsen
Christoffer Læssøe Madsen
RMRasmus Møgelvang
Rasmus Møgelvang
TBTor Biering-Sørensen
Tor Biering-Sørensen
Background: Left atrial (LA) volumes and emptying fraction in the general population may address structural and functional aspects of atrial cardiomyopathy associated with long‐term risk of ischemic stroke in the absence of atrial fibrillation or prior stroke. We investigated the association between LA volumes and function and ischemic stroke. Methods and Results: In a community‐based cohort, we measured LA minimal volume, LA maximal volume, and LA emptying fraction by transthoracic echocardiography. The primary end point was ischemic stroke. Participants with known atrial fibrillation or prior ischemic stroke were excluded, which resulted in 1866 participants. The mean age was 58±16 years, and 57% were women. During a median follow‐up of 16.5 years (interquartile range: 11.4–16.8 years), 176 (9.4%) ischemic strokes occurred. In multivariable cause‐specific regression models and competing risk models with death as a competing risk, LA emptying fraction was associated with ischemic stroke (hazard ratio [HR], 1.14 per 10% decrease [95% CI, 1.02–1.28]) and (subdistribution HR, 1.14 [95% CI, 1.01–1.29]). This association remained when adjusting for participants who developed atrial fibrillation during follow‐up (HR, 1.12 per 10% decrease [95% CI, 1.00–1.26]). Indexed LA volumes were not associated with ischemic stroke in the same models. LA emptying fraction and indexed LA volumes were not associated with all‐cause mortality. Conclusions: Lower LA emptying fraction measured by transthoracic echocardiography was associated with future ischemic stroke independently of incident atrial fibrillation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02993172.

1 August 2017 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
PDF file
BABerglind Adalsteinsdottir
Berglind Adalsteinsdottir
RPRunolfur Palsson
Runolfur Palsson
RDRobert J. Desnick
Robert J. Desnick
MGMarianna Gardarsdottir
Marianna Gardarsdottir
PTPolakit Teekakirikul
Polakit Teekakirikul
GGGunnar Th. Gunnarsson
Gunnar Th. Gunnarsson
Background—: The screening of Icelandic patients clinically diagnosed with hypertrophic cardiomyopathy resulted in identification of 8 individuals from 2 families with X-linked Fabry disease (FD) caused by GLA (α-galactosidase A gene) mutations encoding p.D322E (family A) or p.I232T (family B). Methods and Results—: Familial screening of at-risk relatives identified mutations in 16 family A members (8 men and 8 heterozygotes) and 25 family B members (10 men and 15 heterozygotes). Clinical assessments, α-galactosidase A (α-GalA) activities, glycosphingolipid substrate levels, and in vitro mutation expression were used to categorize p.D322E as a classic FD mutation and p.I232T as a later-onset FD mutation. In vitro expression revealed that p.D322E and p.I232T had α-GalA activities of 1.4% and 14.9% of the mean wild-type activity, respectively. Family A men had markedly decreased α-GalA activity and childhood-onset classic manifestations, except for angiokeratoma and cornea verticillata. Family B men had residual α-GalA activity and developed FD manifestations in adulthood. Despite these differences, all family A and family B men >30 years of age had left ventricular hypertrophy, which was mainly asymmetrical, and had similar late gadolinium enhancement patterns. Ischemic stroke and severe white matter lesions were more frequent among family A men, but neither family A nor family B men had overt renal disease. Family A and family B heterozygotes had less severe or no clinical manifestations. Conclusions—: Men with classic or later-onset FD caused by GLA missense mutations developed prominent and similar cardiovascular disease at similar ages, despite markedly different α-GalA activities.

25 May 2017 in Scandinavian Cardiovascular Journal
Verified
Journal Article
Closed access
CMChristoffer Læssøe Madsen
Christoffer Læssøe Madsen
HBHenning Bundgaard
Henning Bundgaard
ÅRÅse Krogh Rasmussen
Åse Krogh Rasmussen
SSSøren Schwartz Sørensen
Søren Schwartz Sørensen
JPJørgen Holm Petersen
Jørgen Holm Petersen
HPHelle Petri
Helle Petri
Objectives: In patients with Fabry disease (FD), left ventricular hypertrophy and arrhythmias are frequently observed and cardiac involvement is the leading cause of death. Long-term efficacy of enzyme replacement therapy (ERT) on cardiac involvement is unclear. We assessed and compared long-term progression of cardiac involvement according to ERT and non-ERT. Methods: We retrospectively assessed and compared long-term progression of cardiac involvement in adult patients with FD in the nationwide Danish cohort. We followed clinical signs, symptoms and findings by echocardiography, electrocardiography and Holter-monitoring. Results: We included 66 patients; 47 patients (27 women) received ERT (ERT group) and 19 patients (15 women) did not (non-ERT group). The groups were followed for a median of 8 [0–12] years and 6 [0–13] years, respectively. Comparison between ERT and non-ERT receiving patients by left ventricular mass (echocardiographic assessment) and Sokolow-Lyon voltage- and Cornell product criteria (electrocardiographic assessment) revealed no significant differences. In the ERT group, we observed no change in left ventricular mass but a decrease in Sokolow-Lyon voltage- and Cornell product criteria from baseline to follow-up; 30 mm [15–53] vs. 25 mm [3–44], p < 0.005 and 1710 mm·ms [480–3740] vs. 1520 mm·ms [550–5740], p < .05, respectively. There were no changes within the non-ERT group. During follow-up, cardiac symptoms and use of cardiovascular procedures and -medication increased significantly in the ERT group, whereas no differences were observed within the non-ERT group. Discussion: We raise concerns regarding the efficacy and benefit of ERT on cardiac involvement in Fabry disease and stress the need for further research.